Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000947871-25-000543·C4 Therapeutics, Inc.
Schedule 13G ownership disclosure
C4 Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 12529R107
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- OrbiMed Advisors LLC
Shares: 2,174,700.00 · Class: 3.1%
- OrbiMed Capital LLC
Shares: 4,655,600.00 · Class: 6.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000543
- Form type
- SCHEDULE 13G/A
- Filer
- C4 Therapeutics, Inc.
- CIK
- CIK 1662579
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership